IGA Glomerulonephritis (IGA Nephropathy)

A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.

Also Known As:

Networked: 3379 relevant articles (179 outcomes, 443 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Proteinuria
2.	Membranous Glomerulonephritis (Membranous Nephropathy)
3.	Glomerulonephritis
4.	Nephrotic Syndrome (Syndrome, Nephrotic)
5.	Hematuria

Experts

1.	Novak, Jan: 53 articles (07/2015 - 08/2002)
2.	Tomino, Yasuhiko: 50 articles (08/2015 - 08/2002)
3.	Julian, Bruce A: 43 articles (07/2015 - 08/2002)
4.	Suzuki, Hitoshi: 36 articles (08/2015 - 01/2004)
5.	Zhang, Hong: 30 articles (10/2015 - 01/2004)
6.	Leung, Joseph C K: 29 articles (10/2015 - 01/2002)
7.	Lai, Kar Neng: 29 articles (05/2012 - 01/2002)
8.	Wyatt, Robert J: 25 articles (11/2015 - 07/2002)
9.	Suzuki, Yusuke: 24 articles (08/2015 - 11/2005)
10.	Hiki, Yoshiyuki: 24 articles (04/2015 - 01/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to IGA Glomerulonephritis:

1.	Immunoglobulin A (IgA)IBA 07/01/2000 - "Patients with IgA nephropathy and those with HSN showed significantly greater levels of plasma IgA1 antibody against H parainfluenzae than patients with other renal diseases (IgA nephropathy versus other renal diseases, P = 0.008; HSN versus other renal diseases, P = 0.025). " 11/01/2008 - "CD19(+)CD5(+) B cells isolated from patients with untreated IgA nephropathy expressed higher levels of IgA, produced more IFN-gamma, and were more resistant to CD95L-induced apoptosis than cells isolated from control subjects and patients with lupus; these properties reversed with effective treatment of IgA nephropathy. " 06/01/2014 - "The remission criteria of immunoglobulin A (IgA) nephropathy have varied depending on the clinical study. " 11/01/1997 - "Published reports examining the efficacy of fish oil for preserving renal function in immunoglobulin A (IgA) nephropathy have yielded conflicting results. " 01/01/1993 - "Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy."
2.	Antigen-Antibody Complex (Immune Complex)IBA 10/01/1989 - "IgA nephropathy: overproduction or decreased clearance of immune complexes?" 01/01/2008 - "Studies of the properties of immune complexes (IC) in the circulation, urine, and mesangium of IgA nephropathy (IgAN) patients have provided data relevant to the pathogenesis of this disease. " 01/01/1989 - "Immunoelectron microscopic studies of immune complex deposits and basement membrane components in IgA nephropathy." 08/01/1987 - "[Immunological study of IgA nephropathy--relationship of T cell function, monocytes and the circulating immune complex]." 11/01/2015 - "All specimens of immune complex-mediated GN, except two specimens of IgA nephropathy and one specimen of sclerosing membranoproliferative GN, showed bright (2-3+) C4d staining. "
3.	CreatinineIBA 11/01/1995 - "In this study, among patients with biopsy-proven IgA nephropathy, 53 patients in whom creatinine clearance had been monitored over 5 yr were recruited for study. " 08/01/2015 - "We investigated the relationship between changes in dietary PI and both the changes in creatinine clearance and glomerular histomorphometry in adult patients with IgA nephropathy (IgAN). " 07/01/2014 - "The blood pressure, serum creatinine and 24 h urinary protein excretion of patients with IgA nephropathy altered with increasing pathological grade. " 01/01/2008 - "Patients with IgA nephropathy versus controls: DIR 8.80 +/- 6.6 vs. 12.83% (p < 0.01), NAG 7.25 +/- 3.30 vs. 4.69 +/- 1.12 U/g creatinine (p < 0.01), and fractional UA excretion 7.80 +/- 2.20 versus 6.29 +/- 1.80% (p < 0.01). " 11/01/2007 - "Urinary levels of L-FABP and 8-OHdG were higher in patients with IgA nephropathy than in age-matched and sex-matched healthy controls (122.5 +/- 25.5 v 6.4 +/- 3.8 mug/g.creatinine, P < .001; and 22.6 +/- 4.4 v 4.8 +/- 1.4 ng/mg.creatinine, P < .01, respectively). "
4.	MethylprednisoloneFDA LinkGeneric 12/01/2012 - "Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy." 01/01/2008 - "In the current study, we evaluated the efficacy of methylprednisolone (MP) pulse therapy in IgA nephropathy (IgAN) patients with established renal function impairment. " 08/01/1991 - "In order to estimate the effects of methylprednisolone pulse therapy on progressive IgA nephropathy, clinical parameters in eight patients with the disease were compared between before and after the therapy. " 08/01/1991 - "[Effects of methylprednisolone pulse therapy on progressive IgA nephropathy]." 04/01/1989 - "Does methylprednisolone pulse therapy deteriorate the course of rapidly progressive IgA nephropathy?"
5.	Prednisolone (Predate)FDA LinkGeneric 05/01/2003 - "Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy." 01/01/2002 - "Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy." 01/01/2011 - "To investigate this phenomenon, we retrospectively screened and analysed 124 consecutive children (age ≤ 18 years at first biopsy) with newly diagnosed severe IgA nephropathy showing diffuse mesangial proliferation, who received combination therapy or prednisolone alone for 2 years and underwent repeat biopsies. " 05/01/2003 - "A prospective, randomized, controlled trial of low-dose prednisolone therapy was performed in patients with IgA nephropathy with moderate histological characteristics. " 08/01/1998 - "These observations may indicate the age of onset of clinical symptoms in childhood IgA nephropathy affects changes of histologic alterations after receiving prednisolone therapy."
6.	bredinin (mizoribine)IBA 07/01/2002 - "A novel immunosuppressant, mizoribine (MZB), has recently been reported to be effective in the treatment of IgA nephropathy (IgAN), although its mechanism of action remains unknown. " 04/01/2008 - "Recent clinical trials have shown a beneficial effect of mizoribine (Miz), an immunosuppressive drug, in the treatment of new-onset pediatric IgA nephropathy (IgAN). " 11/01/2015 - "Single-course steroid pulse therapy combined with mizoribine was considered to have a protective effect on the renal function in IgA nephropathy, especially accompanying renal dysfunction." 05/01/2008 - "Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study." 04/01/2008 - "Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy."
7.	Adrenal Cortex Hormones (Corticosteroids)IBA 01/01/1996 - "These results indicate that corticosteroids are beneficial in stabilizing the renal function for a long time during the early stage of progressive IgA nephropathy, although this study was not a randomized one." 06/01/2015 - "Glomerular disease: Efficacy of corticosteroids in high-risk IgA nephropathy." 02/01/2000 - "We conclude that early treatment with corticosteroids for adult diffuse proliferative IgA nephropathy is effective in reducing renal injury." 02/01/2000 - "To determine whether early treatment with corticosteroids ameliorates the proliferative lesions of diffuse proliferative IgA nephropathy, we conducted a prospective, randomized, controlled trial. " 09/01/2015 - "Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study."
8.	Prednisone (Sone)FDA LinkGeneric 02/01/2014 - "Combination therapy with MMF and prednisone for severe IgA nephropathy achieved a higher remission rate compared to treatment with CYC and prednisone. " 10/01/1993 - "Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone." 04/01/1993 - "In a short-term double-blind, crossover trial, prednisone had no effect on IgA nephropathy. " 02/01/2014 - "Patients (n = 84) with severe IgA nephropathy received either MMF/prednisone (MMF group) or CYC/prednisone (CYC group). " 01/01/2009 - "Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial."
9.	Idiopathic minimal change nephrotic syndromeIBA 01/01/2004 - "Sustained remission was more likely in cases of GN (minimal change disease and IgA nephropathy) and ACEI-ARB treatment (P <.01). " 06/01/2015 - "Forty LN patients, 40 SLE patients without kidney injury, 63 immunoglobulin A nephropathy (IgAN) patients, 20 minimal change disease (MCD) patients and 33 healthy controls were included in the present study. " 10/01/2007 - "The objective of the present study is to investigate whether human mast cells (MC) contribute to renal damage through local activation of the renin-angiotensin system, by assessing their numbers in renal biopsy specimens from patients with IgA nephropathy (IgAN) or minimal change nephrotic syndrome (MCNS). " 01/01/2015 - "Clinical characteristics of concomitant nephrotic IgA nephropathy and minimal change disease in children." 06/06/2014 - "IgA nephropathy with minimal change disease."
10.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/01/2001 - "Although several in vitro studies and clinical observations suggest that ACE-inhibitors (ACE-I) are a promising treatment for IgA nephropathy (IgAN), meta-analysis of published data is not yet conclusive. " 05/01/2004 - "The COOPERATE trial, in which 50% of the subjects had IgA nephropathy, established that ACE inhibitors and ARBs preserve renal function equally, and that dual ACE inhibitor-ARB therapy preserves renal function more effectively than either therapy alone. " 05/01/2004 - "To determine whether ACE inhibitors or ARBs preserve renal function long-term, one must rely on trials studying nondiabetic, proteinuric renal diseases rather than on trials specific to IgA nephropathy. " 06/01/2003 - "Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial." 01/01/2006 - "IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors."

Therapies and Procedures

1.	Tonsillectomy 10/01/2009 - "Tonsillectomy and steroid pulse (TSP) therapy was proposed as a curative treatment for IgA nephropathy by Hotta et al. (Am J Kidney Dis 38:736-742, 2001) based on data that about 50% of patients achieved clinical remission (CR) of urinary abnormalities. " 01/01/2009 - "To review pediatric cases of IgA nephropathy (IgAN) in 6 patients who underwent tonsillectomy and had marked improvement of their renal symptoms and to review the appropriate indications for tonsillectomy for this disease. " 07/01/2012 - "Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy." 01/01/2007 - "Recently we reported a significant impact of tonsillectomy and steroid pulse therapy on clinical remission in our IgA nephropathy (IgAN) patients and indicated that clinical remission might terminate the progressive deterioration in renal function. " 10/01/2001 - "Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy."
2.	Kidney Transplantation 01/01/1999 - "Recurrence of IgA nephropathy (IgAN) following renal transplantation has been described in 40-50% of such patients and it usually has a good outcome. " 01/01/1990 - "Recurrence of IgA nephropathy following renal transplantation has been described in 40-50% of patients, and it usually has a good outcome. " 04/01/2013 - "Risk factors for recurrence of immunoglobulin a nephropathy after renal transplantation: single center study." 07/01/2012 - "Renal transplantation outcome in selected recipients with IgA nephropathy as native disease: a bicentric study." 10/01/2007 - "This study was performed to determine the frequency of relapsing crescentic IgA nephropathy after kidney transplantation. "
3.	Drug Therapy (Chemotherapy) 01/01/2011 - "Antithrombotic drug therapy for IgA nephropathy: a meta analysis of randomized controlled trials." 11/01/2006 - "Efficacy of tonsillectomy pulse therapy versus multiple-drug therapy for IgA nephropathy." 12/01/2001 - "For 19 patients undergoing chemotherapy (85 courses), 69 patients with IgA nephropathy and 16 patients with Henoch-Schölein purpura nephritis, the number of excreted GEC and GEC casts were counted by an immunofluorescent study. " 01/01/1999 - "The present study investigated the prevalence of white-coat hypertension, the diurnal rhythm of blood pressure (BP), the effectiveness of antihypertensive drug therapy, and the effect of the above on the progression of the kidney disease in IgA nephropathy. " 01/01/2012 - "Agonists of PPARγ exert protective effects against various kidney diseases including diabetic nephropathy, ischemic renal injury, IgA nephropathy, chemotherapy-associated kidney damage, polycystic kidney diseases and age-related kidney diseases via both systemic and renal actions. "
4.	Transplants (Transplant) 06/01/2015 - "The purpose of this study was to investigate immunoglobulin A nephropathy recurrence rate after transplant in children and adults and to identify recurrence rates by clinical progression before transplant. " 09/01/2008 - "However, more recent studies with longer follow-up have shown that posttransplantation IgA nephropathy may be a significant contributor to graft loss. " 02/01/1994 - "Actuarial survival rate of kidney transplants in patients with IgA glomerulonephritis: a one-center study." 06/01/2015 - "There were 56 patients with immunoglobulin A nephropathy who had renal transplant between 1989 and 2005. " 06/01/2015 - "Different Recurrence Rates Between Pediatric and Adult Renal Transplant for Immunoglobulin A Nephropathy: Predictors of Posttransplant Recurrence."
5.	Transplantation (Transplant Recipients) 09/01/2015 - "The first recipient was a 26-year-old man who experienced biopsy-proven IgA nephropathy 10 months post-transplantation. " 06/01/2014 - "IgA nephropathy (IgAN) is recurrent after transplantation; however, its time of recurrence is unpredictable. " 01/01/2014 - "Transplantation of endothelial progenitor cells in treating rats with IgA nephropathy." 06/27/2013 - "Usefulness of Oxford classification in assessing immunoglobulin A nephropathy after transplantation." 04/01/2013 - "Recipients with recurrent IgA nephropathy after transplantation, especially younger patients, need to be followed up carefully."